Table 1 Brief characteristics of the included studies: median (minimum–maximum)
| Â | OS | ALSFRS-R | ALL |
|---|---|---|---|
Number of arms | 30 | 29 | 59 |
Sample size per arm | 100 (11–468) | 52 (11–441) | 75 (11–468) |
Age, year | 56.2 (53.5–64.6) | 56.0 (51.2–60.5) | 56.1 (51.2–64.6) |
Gender, male% | 64 (45.5–71) | 61.3 (45.5–72.0) | 61.3 (45.5–72) |
Disease duration, month | 17.8 (9–36) | 17.5 (9.6–26.4) | 17.6 (9–36) |
Riluzole therapy, % | 90.95 (0–100) | 96.45 (50–100) | 87.75 (0–100) |
ALSFRS-R score at baseline | 38.1 (30.74–42) | 38.15 (32.6–43.24) | 38.1 (30.74–43.24) |